In a fast-moving market like healthcare, speed matters. Metys®, from Symphony Health, an ICON plc company, delivers weekly insights up to 3 days faster than other platforms – so you can respond to competitive shifts wi...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
The Significant Role of a Robust Regulatory Intelligence Process in Global Safety Submissions
Pharmacovigilance insights on the efforts towards the international standardisation of electronic transmission of drug safety information to achieve a unified objective of patient safety, written by Arinder Sihota and Trupti Gurjar, which featured in the March 2020 edition of Pharma Focus.
-
Is Pharma Finally Heading for Launch Excellence?
The traditional approaches to launching a new medicine still tend to sit in the commercial function, but they need to better align with HEOR, medical affairs and clinical teams. Read more in the February issue of PME.
-
-
Can Digital Technologies and AI improve R&D productivity enough to restore ROI?
A thought leadership article authored by Tom O’Leary, exploring what can be done to help ensure return on investment in clinical trials.
-
Making a Difference
How can we encourage more women to pursue STEM careers? Read how ICON is playing a part in this recent Conversis article.
-
10 Professionals Predict the Future of Clinical Trials
Discover what the future of clinical trials holds, according to ICON'S Senior Director of Business Development, Sarah Ikard, MBA as recorded by Xtalks in their interview with her at the recent DIA 2019 conference.
-
ICER's Growing Impact On Drug Pricing And Reimbursement
Read Forbes' original article referencing the ICON whitepaper ‘The Role of ICER as an Independent HTA Organisation’, exploring how ICER may have a greater impact on payer decision-making than expected and can be viewed as a ‘decision resource’ for budgetary and formulary policy decision making.
